Houston, Texas--(Newsfile Corp. - July 15, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that the State of Texas has approved the Company's license to manufacture and distribute consumable hemp products. This approval turns years of vision, science, and preparation into action and marks the moment CBIH steps into the market and begins commercial distribution.
The Company expects initial distribution to begin within the next 30 days, following years of scientific development, product formulation, regulatory preparation, and commercialization planning. The timing is especially significant as today, July 15, 2026, the federal hearings examining the proposed rescheduling of cannabis from Schedule I to Schedule III reached their conclusion. CBIH believes this process could help advance a more science-based regulatory framework, expand opportunities for cannabinoid research, and create a clearer path for responsible commercial innovation across the industry.
"For years, we have worked toward this moment with conviction, discipline, and a clear vision for the future," said Dante Picazo, Chief Executive Officer of CBIH. "Receiving our Texas license at one of the most consequential turning points in modern cannabis history transforms this achievement into something far greater than regulatory approval. It marks the moment when preparation becomes execution, science moves closer to the consumer, and long-term vision enters the marketplace. We believe 2026 will be remembered as the year the industry began to redefine itself, and today, CBIH is stepping forward to help shape what comes next."
The initial commercial rollout will introduce VitaCookies, CBIH's market-ready functional wellness cookie line formulated with selected cannabinoid and nutritional ingredients and developed through a disciplined process of product formulation, regulatory compliance, quality control, and consumer-focused innovation. The product line is positioned within high-interest wellness categories associated with menopause support, everyday discomfort, stress management, relaxation, emotional balance, and broader mental well-being. Strategically, VitaCookies represents the first commercial expression of CBIH's integrated business model, bringing together cannabinoid innovation, scientific development, intellectual property, brand creation, and scalable distribution to support revenue generation, portfolio expansion, and long-term shareholder value.